We are live on ! Find out more
LFWD icon

ReWalk Robotics

7.11 USD
-0.01
0.14%
At close Updated Sep 14, 4:00 PM EDT
1 day
-0.14%
5 days
1.72%
1 month
-4.56%
3 months
2.16%
6 months
-3.79%
Year to date
-4.95%
1 year
5.33%
5 years
-93.23%
10 years
-99.94%
 

About: Lifeward Ltd is a medical device company that designs, develops, and commercializes life-changing solutions spanning the continuum of care in physical rehabilitation and recovery, delivering functional and health benefits in clinical settings as well as in the home and community. Its product offerings include the ReWalk Personal Exoskeleton, ReStore Exo-Suit, MYOLYN FES Cycling, and AlterG Anti-Gravity Systems. The company operates in the United States, which generates the majority of its revenue, as well as in Europe, Germany, Asia Pacific, and the rest of the world.

Employees: 81

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 0%
Neutral 85.7%
Negative 14.3%
Neutral
GlobeNewsWire
6 days ago
Lifeward Publishes Updated Investor Presentation Highlighting Commercial Growth Strategy
HUDSON, Mass. and YOKNEAM ILLIT, Israel, Sept.
Lifeward Publishes Updated Investor Presentation Highlighting Commercial Growth Strategy
Neutral
GlobeNewsWire
14 days ago
Lifeward Appoints Josh Hexter Interim Chief Executive Officer and Rami Aviram Chief Financial Officer
Experienced leadership team to build on established commercial platform and accelerate Lifeward's next phase of growth with continuity of strategy Experienced leadership team to build on established commercial platform and accelerate Lifeward's next phase of growth with continuity of strategy
Lifeward Appoints Josh Hexter Interim Chief Executive Officer and Rami Aviram Chief Financial Officer
Negative
Zacks Investment Research
1 month ago
Lifeward (LFWD) Reports Q2 Loss, Misses Revenue Estimates
Lifeward (LFWD) came out with a quarterly loss of $1.46 per share versus the Zacks Consensus Estimate of a loss of $1.49. This compares to a loss of $6.96 per share a year ago.
Lifeward (LFWD) Reports Q2 Loss, Misses Revenue Estimates
Neutral
GlobeNewsWire
1 month ago
Lifeward Reports Strong Second Quarter 2026 Financial Results as Commercial Execution Drives Growth
Revenue increase and operating performance improve as capital-efficient distribution strategy gains momentum Strengthened balance sheet and expanding rehabilitation platform support con tinued commercial execution HUDSON, Mass. and YOKNEAM ILLIT, Israel, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd.
Lifeward Reports Strong Second Quarter 2026 Financial Results as Commercial Execution Drives Growth
Neutral
GlobeNewsWire
1 month ago
Lifeward to Report Second Quarter 2026 Financial Results on August 14, 2026
HUDSON, Mass. and YOKNEAM ILLIT, Israel, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a diversified biomedical innovation company with a portfolio of commercialized neurorehabilitation products and a biomedical pipeline, today announced the Company will report its second quarter 2026 financial results on Friday, August 14, 2026. A press release will be issued and quarterly report will be filed with the SEC prior to 9:30 a.m. ET. The Company will not conduct a conference call.
Lifeward to Report Second Quarter 2026 Financial Results on August 14, 2026
Neutral
GlobeNewsWire
1 month ago
Lifeward Launches Pilot Program with Ottobock Care to Expand National Access to ReWalk® Personal Exoskeleton
Ottobock Care , one of the leading mobility technology patient care organizations in the U.S. , bring s extensive clinical expertise and patient care infrastructure A dvances Lifeward's strategy to broaden ReWalk access through capital-efficient channel partner model intended to accelerate growth, expand patient access and improve commercial scalability HUDSON, Mass. and YOKNEAM ILLIT, Israel, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd.
Lifeward Launches Pilot Program with Ottobock Care to Expand National Access to ReWalk® Personal Exoskeleton
Neutral
GlobeNewsWire
2 months ago
Lifeward Secures Growth Capital to Accelerate Commercial Expansion with Up to $11.2 Million in Strategic Financing
Initial $5.6 million provides immediate capital to accelerate commercialization of Lifeward's restorative healthcare platform; additional $5.6 million available upon achievement of defined commercial and financial milestones Initial $5.6 million provides immediate capital to accelerate commercialization of Lifeward's restorative healthcare platform; additional $5.6 million available upon achievement of defined commercial and financial milestones
Lifeward Secures Growth Capital to Accelerate Commercial Expansion with Up to $11.2 Million in Strategic Financing
Neutral
GlobeNewsWire
3 months ago
Lifeward Appoints Dr. Keith D. Rose as Chief Medical Officer to Support Expansion of Neurorehabilitation Portfolio and Advance Biomed Platform
Veteran physician , medical affairs and clinical research leader brings 30 years of rehabilitation medicine experience and deep expertise in neuroscience , mobility technologies , and metabolic disease
Lifeward Appoints Dr. Keith D. Rose as Chief Medical Officer to Support Expansion of Neurorehabilitation Portfolio and Advance Biomed Platform
Neutral
Seeking Alpha
4 months ago
Lifeward Ltd. (LFWD) Q1 2026 Earnings Call Transcript
Lifeward Ltd. (LFWD) Q1 2026 Earnings Call Transcript
Lifeward Ltd. (LFWD) Q1 2026 Earnings Call Transcript
Negative
Zacks Investment Research
4 months ago
Lifeward (LFWD) Reports Q1 Loss, Lags Revenue Estimates
Lifeward (LFWD) came out with a quarterly loss of $6.7 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to a loss of $5.52 per share a year ago.
Lifeward (LFWD) Reports Q1 Loss, Lags Revenue Estimates
Price charts implemented using Lightweight Charts™